NASDAQ:OCUP
Ocuphire Pharma, Inc. Stock News
$1.76
+0.0500 (+2.92%)
At Close: May 24, 2024
Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy
11:30am, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
Successful Execution and Completion of Enrollment in Four Late-Stage Clinical Trials Across Nyxol and APX3330 Programs in First Quarter of 2022
Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference
02:27pm, Thursday, 10'th Mar 2022 GlobeNewswire Inc.
FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing ther
Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference
09:27am, Thursday, 10'th Mar 2022
FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
01:29pm, Thursday, 10'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer
Merc
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day
11:00am, Monday, 31'st Jan 2022 GlobeNewswire Inc.
New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia
Ocuphire Pharma (OCUP) Stock: Why The Price Surged Today
07:58am, Wednesday, 24'th Nov 2021
The stock price of Ocuphire Pharma Inc (NASDAQ: OCUP) increased by over 65% pre-market today. This is why it happened.
Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
03:00pm, Thursday, 18'th Nov 2021 Zacks Investment Research
Ocuphire Pharma, Inc. (OCUP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:28am, Thursday, 18'th Nov 2021
Ocuphire Pharma, Inc. (OCUP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022
New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related Ma
FARMINGTON HILLS, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 03'rd Sep 2021
FARMINGTON HILLS, Mich., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely
Ocuphire Pharma Presenting at Two Conferences in August
07:30am, Friday, 06'th Aug 2021
Canaccord Genuity 41 st Annual Growth Conference being held virtually on August 10-12, 2021
Ocuphire Pharma: An Undervalued Ophthalmic Play
04:11pm, Thursday, 05'th Aug 2021
Ocuphire is positioning itself as a leading ophthalmic player, providing novel therapeutic solutions for both front and back of the eye indications.
Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Dise
